| Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia |
299 |
| iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL |
169 |
| Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party |
141 |
| The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas |
133 |
| Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome |
121 |
| Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia |
112 |
| Recommendations for the management of hemophagocytic lymphohistiocytosis in adults |
103 |
| CTLA-4: a moving target in immunotherapy |
100 |
| GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts |
86 |
| Single-agent ibrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience |
80 |
| Anemia of inflammation |
80 |
| Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms |
76 |
| Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet |
72 |
| Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib |
66 |
| PD-1 expression and clinical PD-1 blockade in B-cell lymphomas |
65 |
| Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma |
63 |
| Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma |
60 |
| Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial |
59 |
| Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD |
57 |
| Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL |
56 |
| A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403 |
55 |
| Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies |
53 |
| Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma |
53 |
| CD38 antibodies in multiple myeloma: back to the future |
52 |
| Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study |
51 |
| The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL |
51 |
| Iron deficiency |
51 |
| Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma |
50 |
| Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy |
50 |
| Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy |
48 |
| Age-related clonal hematopoiesis |
48 |
| Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study |
48 |
| Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087 |
47 |
| Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome |
46 |
| Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML |
45 |
| Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL |
45 |
| The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia |
45 |
| First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation |
45 |
| Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib |
45 |
| Aging of hematopoietic stem cells |
44 |
| Activity of the PI3K-delta,gamma inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma |
43 |
| Duvelisib, a novel oral dual inhibitor of PI3K-delta,gamma, is clinically active in advanced hematologic malignancies |
43 |
| Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease |
42 |
| gamma-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma |
42 |
| Neutrophils and NETs in modulating acute and chronic inflammation |
42 |
| Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML |
41 |
| Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B |
40 |
| International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease |
40 |
| Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study |
40 |
| Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia |
40 |
| A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib |
40 |
| Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab |
40 |
| TIGIT immune checkpoint blockade restores CD8(+) T-cell immunity against multiple myeloma |
39 |
| Neutrophil plasticity in the tumor microenvironment |
39 |
| Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma |
39 |
| A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors |
39 |
| Anemia at older age: etiologies, clinical implications, and management |
38 |
| Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin |
38 |
| Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma |
37 |
| Erythroferrone inhibits the induction of hepcidin by BMP6 |
37 |
| Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR |
36 |
| Chimeric antigen receptor-modified T cells: CD19 and the road beyond |
36 |
| Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma |
35 |
| Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse |
35 |
| Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL |
35 |
| Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells |
35 |
| Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications |
35 |
| Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma |
35 |
| CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells |
35 |
| Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia |
35 |
| Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma |
34 |
| A landscape of germ line mutations in a cohort of inherited bone marrow failure patients |
34 |
| How I treat disseminated intravascular coagulation |
34 |
| Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma |
33 |
| Impact of gut colonization with butyrate-producing microbiota on respiratory viral infection following allo-HCT |
33 |
| High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy |
33 |
| Liver iron sensing and body iron homeostasis |
33 |
| Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL |
31 |
| Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma |
31 |
| Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma |
31 |
| Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents |
31 |
| Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy |
31 |
| Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma |
31 |
| Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations |
31 |
| Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy |
31 |
| Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial |
30 |
| Platelets and vascular integrity: how platelets prevent bleeding in inflammation |
30 |
| Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies |
30 |
| Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis |
30 |
| MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD |
30 |
| Prevention of transfusion-transmitted infections |
30 |
| The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells |
30 |
| The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy |
30 |
| Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML |
29 |
| Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables |
29 |
| Mass cytometry of Hodgkin lymphoma reveals a CD4(+) regulatory T-cell-rich and exhausted T-effector microenvironment |
29 |
| Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact |
29 |
| Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis |
29 |
| Unrelated donor vs HLA-haploidentical alpha/beta T-cell- and B-cell-depleted HSCT in children with acute leukemia |
29 |
| Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma |
29 |
| Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders |
29 |
| Coagulation factor XII in thrombosis and inflammation |
29 |
| Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis |
28 |
| TNF-alpha driven inflammation and mitochondrial dysfunction define the platelet hyperreactivity of aging |
28 |
| PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells |
28 |
| Redirecting T cells to hematological malignancies with bispecific antibodies |
28 |
| Transfusion-associated circulatory overload and transfusion-related acute lung injury |
28 |
| Lineage restriction analyses in CHIP indicate myeloid bias for TET2 and multipotent stem cell origin for DNMT3A |
28 |
| Frailty and the management of hematologic malignancies |
27 |
| Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation |
27 |
| Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients |
27 |
| Hypertension and incident cardiovascular events following ibrutinib initiation |
27 |
| Genetics of diffuse large B-cell lymphoma |
27 |
| A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia |
26 |
| Activated stromal cells transfer mitochondria to rescue acute lymphoblastic leukemia cells from oxidative stress |
26 |
| NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications |
26 |
| Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease |
26 |
| Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignancies |
26 |
| Arterial thromboembolic events preceding the diagnosis of cancer in older persons |
26 |
| Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type |
26 |
| Biology and treatment of Richter syndrome |
26 |
| New therapies for hemophilia |
26 |
| Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia |
26 |
| Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis |
26 |
| Exploring traditional and nontraditional roles for thrombomodulin |
26 |
| Inflammation, von Willebrand factor, and ADAMTS13 |
26 |
| Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation |
26 |
| A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma |
25 |
| Human megakaryocytes possess intrinsic antiviral immunity through regulated induction of IFITM3 |
25 |
| Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea |
25 |
| Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma |
25 |
| Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma |
25 |
| Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients |
25 |
| A single-cell hematopoietic landscape resolves 8 lineage trajectories and defects in Kit mutant mice |
25 |
| Ferritin is secreted via 2 distinct nonclassical vesicular pathways |
25 |
| Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy |
24 |
| PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype |
24 |
| Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma |
24 |
| Intravascular large B-cell lymphoma: a chameleon with multiple faces and many masks |
24 |
| SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery |
24 |
| Sepsis alters the transcriptional and translational landscape of human and murine platelets |
24 |
| Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8(+) T cells and impede CAR T-cell efficacy |
24 |
| PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation |
24 |
| The multifaceted role of fibrinogen in tissue injury and inflammation |
24 |
| High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology |
24 |
| DNA damage responses and p53 in the aging process |
23 |
| Development of T-cell immunotherapy for hematopoietic stem cell transplantation recipients at risk of leukemia relapse |
23 |
| Update on mantle cell lymphoma |
23 |
| Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population |
23 |
| Charcot-Leyden crystal formation is closely associated with eosinophil extracellular trap cell death |
23 |
| Splenectomy for immune thrombocytopenia: down but not out |
23 |
| The rise of apoptosis: targeting apoptosis in hematologic malignancies |
23 |
| An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma |
23 |
| Update on clinical gene therapy for hemophilia |
23 |
| Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies |
23 |
| Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study |
23 |
| Mechanisms of platelet clearance and translation to improve platelet storage |
23 |
| circMYBL a circRNA from MYBL regulates FLT3 translation by recruiting PTBP1 to promote FLT3-ITD AML progression |
22 |
| A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia |
22 |
| Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma |
22 |
| Treatment of MDS |
22 |
| Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years |
22 |
| von Willebrand factor regulation of blood vessel formation |
22 |
| BCL-2 inhibition in AML: an unexpected bonus? |
22 |
| CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells |
22 |
| Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia |
22 |
| The MYC oncogene is a global regulator of the immune response |
22 |
| Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma |
22 |
| R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma |
22 |
| Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial |
21 |
| RhoA G17V is sufficient to induce autoimmunity and promotes T-cell lymphomagenesis in mice |
21 |
| How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia |
21 |
| Deficiency of adenosine deaminase 2 triggers adenosine-mediated NETosis and TNF production in patients with DADA2 |
21 |
| Genetics of MDS |
21 |
| Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL |
21 |
| Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human beta-globin locus |
21 |
| Parsaclisib, a potent and highly selective PI3K delta inhibitor, in patients with relapsed or refractory B-cell malignancies |
21 |
| Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade |
20 |
| Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma |
20 |
| Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial |
20 |
| A novel irreversible FLT3 inhibitor, FF-1 shows excellent efficacy against AML cells with FLT3 mutations |
20 |
| Mechanisms of immune escape after allogeneic hematopoietic cell transplantation |
20 |
| Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with beta-thalassemia |
20 |
| A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome |
20 |
| Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis |
20 |
| Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy |
20 |
| Chronic immune response dysregulation in MDS pathogenesis |
20 |
| GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia |
20 |
| alpha(1)-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease |
20 |
| Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura |
20 |
| A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease |
20 |
| Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study |
20 |
| The potential role of gamma delta T cells after allogeneic HCT for leukemia |
20 |
| Activated protein C, protease activated receptor and neuroprotection |
20 |
| How I manage monoclonal gammopathy of undetermined significance |
20 |
| Definitive radiotherapy for localized follicular lymphoma staged by F-18-FDG PET-CT: a collaborative study by ILROG |
19 |
| Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stemcell self-renewal advantage |
19 |
| High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies |
19 |
| How I treat CLL patients with ibrutinib |
19 |
| A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma |
19 |
